公开(公告)号：US20240319196A1

公开(公告)日：2024-09-26

申请号：US18576514

申请日：2022-07-06

Applicant: Creatv Micro Tech Inc.

Inventor： Daniel L. Adams ,  Cha-Mei TANG

IPC: G01N33/574 ,  G01N33/569 ,  G01N33/68

CPC classification number: G01N33/57492 ,  G01N33/56972 ,  G01N33/6872

Abstract: Means for predicting (i) multiple organ metastasis and/or multifocal metastatic disease and (ii) overall survival (OS) and progression free survival (PFS) of subjects having cancer are disclosed, where the predictions are based on the number and size of circulating cancer associated macrophage-like cells (CAMLs) found in a biological sample, such as blood, from the subject.

公开(公告)号：US20140302526A1

公开(公告)日：2014-10-09

申请号：US14355247

申请日：2012-11-02

Applicant: Creatv Micro Tech, Inc.

Inventor： Cha-Mei Tang ,  Peixuan Zhu

IPC: G01N33/574

CPC classification number: G01N33/57407 ,  G01N33/57426 ,  G01N33/582 ,  G01N2800/56

Abstract: Detection of ZAP-70 expression provides important information about disease progression and overall survival in patients with chronic lymphocytic leukemia (CLL). The invention provides methods for diagnosing CLL in a subject, as well as methods for clearly distinguishing CLL patients with aggressive form of the disease. A consistent number of B cells from patient blood is isolated and lysed to release all of the intracellular ZAP-70 protein. The released ZAP-70 protein is subsequently extracted by immunomagnetic separation followed by detection with fluorescence immunosandwich assay. The ZAP-70 fluorescence signal is measured with Signalyte™-II spectrofluorometer. The VeriZAP™ assay is a simple, reliable, and reproducible method for quantitative detection of ZAP-70 in patient leukemic cells, and can be used as a prognostic test to distinguish indolent versus aggressive CLL patients.

Abstract translation: ZAP-70表达检测提供了有关慢性淋巴细胞性白血病（CLL）患者疾病进展和总体生存的重要信息。 本发明提供了用于诊断受试者中CLL的方法，以及用于清楚地区分CLL患者与侵袭性疾病形式的方法。 分离来自患者血液的一致数量的B细胞并裂解以释放所有细胞内ZAP-70蛋白。 随后通过免疫磁性分离提取释放的ZAP-70蛋白，随后用荧光免疫分析法检测。 使用Signalyte™-II分光光度计测量ZAP-70荧光信号。 VeriZAP™测定法是用于定量检测患者白血病细胞中ZAP-70的简单，可靠和可重复的方法，可用作预后评估来区分无痛与侵袭性CLL患者。

公开(公告)号：US20130330721A1

公开(公告)日：2013-12-12

申请号：US13854003

申请日：2013-03-29

Applicant: Creatv Micro Tech, Inc.

Inventor： Cha-Mei Tang ,  Yunqi Zhang

IPC: G01N1/40 ,  B01D29/00

CPC classification number: G01N33/5005 ,  B01D29/00 ,  B01D39/16 ,  B01D39/1692 ,  B01L3/50 ,  B01L3/502 ,  B01L3/5635 ,  B01L9/00 ,  B01L2300/0681 ,  G01N1/4005 ,  G01N1/4077 ,  G01N2001/4088 ,  Y10T29/49826 ,  Y10T29/49963

Abstract: A microfilter comprising a polymer layer formed from photo-definable dry film, and a plurality of apertures each extending through the polymer layer. A microfilter comprising two or more polymer layers formed from photo-definable dry film, and a plurality of apertures or open areas each extending through the polymer layer. Methods of forming apertures in one or more layers of photo-definable dry film are also disclosed. Filter holder designs and methods appropriate to hold microfilters to collect the rare cells and to perform of assays in the filter holder are provided. Microfiltration chip designs and methods appropriate to collect the rare cells and to perform assays in the microfluidic chips are provided. The invention also describes the use of the microfilter, filter holder and microfilter chips to collect rare cells from body fluids and perform assays, and these rare cells can be used for medical and biological research applications.

Abstract translation: 一种包含由光可定义干膜形成的聚合物层的微过滤器和各自延伸穿过聚合物层的多个孔。 包括由可光限定的干膜形成的两个或更多个聚合物层的微滤器以及各自延伸穿过聚合物层的多个孔或开口区域。 还公开了在一个或多个光可定义干膜层中形成孔的方法。 提供了适用于容纳微型过滤器以收集稀有细胞并在过滤器保持器中执行测定的过滤器支架设计和方法。 提供了适用于收集稀有细胞并在微流控芯片中进行测定的微滤芯片设计和方法。 本发明还描述了微型过滤器，过滤器保持器和微过滤器芯片用于从体液中收集稀有细胞并进行测定的用途，并且这些稀有细胞可用于医学和生物研究应用。